Department of Pharmaceutical Chemistry, BLDEA’s SSM College of Pharmacy and Research Centre Vijayapura-586103, Karnataka, India.
An in-silico ADME/T study utilizing Swiss ADME software was conducted on novel derivatives of standard antidiabetic drugs, revealing reduced toxicity levels compared to existing medications. Docking scores showed significant interactions with antidiabetic and antitubercular properties, successfully binding to protein PDB IDs 8Q0T and 1H5U. Predictive analysis yielded Pa and Pi values (0-1), indicating promising antidiabetic activity. These findings suggest the derivatives' potential for development into enhanced efficacy antidiabetic compounds, opening new avenues for antidiabetic drug discovery and providing valuable leads for future research in combating diabetes.
In chemistry, "docking" often refers to a computational method used in molecular modeling to predict how small molecules, such as drugs, interact with larger molecules, such as proteins or enzymes. This technique is instrumental in drug discovery and design.1 Here’s a breakdown of how docking works: The process involves placing a small molecule (the ligand) into the requisite site of a larger fragment (the target, usually a protein) to predict how well they fit together. The goal is to find the optimal orientation and conformation of the ligand that maximizes its interaction with the target.2 In the context of chemistry, particularly in drug development and pharmaceuticals, ADME, and toxicity are crucial for understanding how compounds behave in biological systems.3 Refers to the adverse effects a compound can have on an organism. It involves studying the harmful effects that can occur at various concentrations and understanding the safety margin between therapeutic and toxic doses.4 Together, ADME and toxicity studies help predict a compound’s behavior in the body, its effectiveness, and its safety profile, guiding the development of new drugs and chemicals.5 Numerous physiological functions were predicted using the online communication PASS (prediction of activity profiles for compounds; http://www.pharmaexpert.ru/ PASS online/ index.php). According to Kumaresan et al. (2015), this instrument was developed to predict a variety of biological processes with 95?curacy.6 The structures were created in ChemDraw 16.0, translated to Smiles format, and used with the PASS online version to predict the biological spectrum (Kawsar et al. 2022a). The outcome was displayed as the likelihood of the active substance, Pa, and the inactive substance, Pi. In the range of 0.000–1.000, Pa > Pi is taken into consideration here, and Pa + Pi ? 1 generally.7 The PASS prediction results were interpreted and applied with flexibility: [i] the prospect of discovery of the movement empirically is in elevation when Pa > 0.5; [ii] the possibility of conclusion the action empirically is lesser if 0.5 < Pa>
MATERIALS AND METHODS:
The docking investigations are performed to evaluate the different forms of bimolecular connections and ligand-receptor attachment intensities. PyRX, PyMOL, Biovia Discovery Studios 2020, Auto dock Vina, and other tools were used for these docking studies. Proteins were used in the docking investigation, specifically Polyketide synthase, an antitubercular amino acid, and its structure in crystals. PKS13 (PDB ID: 8Q0U) The enzyme glycogen phosphorylase is an anti-diabetic protein (PDB ID: 1H5U). An AMD Ryzen 7 3700U processor powered an HP 15s-eq0132au computer, which was utilized for the statistical task.
Proteins assembly
The RCSB Proteins The information a bank provided the crystalline structure of the antitubercular amino acids Polyketide synthesis the PKS13 (PDB ID: 8Q0U) as well as the anti-diabetic amino acids Glycogen phosphorylase (PDB ID: 1H5U). The amino acids were generated using the Swiss PDB viewers to remove the remaining agonists, and the resulting amino acids have been retained in the form of a PDB.
The Ligand setup
The three-dimensional models for the molecules were generated utilizing a chem sketch and submitted in BIOVIA Discovery Studio Visualizer-2020. A clustered sdf file had been generated after ligands reduction was completed utilizing the "A SMALL MOLECULES" procedure in BIOVIA Discovery Studios the Visualizer feature-2020.
Docking studies
Docking investigations become more important to minimize mistakes and determine the proper position of compounds inside the protein's active region. PyRx-Virtual Evaluation Tools was utilized to do the docking process. In the PyRx-Virtual Screens Instrument change ligands to pdbqt, then choose those as ligands in the Vina tutorial. ready-to-use proteins have been imported into the PyRx-Virtual Screening Tool and marked for macro molecule selection. The calculation of the binding-related amino acids and connection energy—the relationship between the substance that binds and the receptor was done.
Research on Drugs Likelihood
DruLiTO was used to import the chosen phytonutrients in sdf file and perform the therapeutic likelihood testing ADME/T Studies. The Swiss ADME/T was used to download the SMILES of the chosen compounds while saving their ADME/T attributes. Scores have been summarized as shown in the table.
Predictions for PASS
The shortlisted compounds' SMILES were entered into the validation phase of the digital way2drug program.
RESULTS AND DISCUSSION
The following are the smiles of some standard antidiabetic drugs with their derivatives:
ADMET PREDICTION RESULTS:
PASS PREDICTION:
Successfully demonstrated the potential of novel derivatives of standard antidiabetic drugs, exhibiting reduced toxicity and enhanced efficacy through in-silico ADME/T studies and molecular docking. The significant interactions with antidiabetic and antitubercular properties, confirmed by docking with protein PDB IDs 8Q0T and 1H5U, and predictive Pa and Pi values (0-1), underscore the promise of these derivatives as next-generation antidiabetic compounds. This study provides valuable leads for future research, paving the way for the development of more effective and safer antidiabetic therapies, and highlighting the potential of computational drug design in accelerating the drug discovery process.
ACKNOWLEDGEMENT
My greatest thanks goes out to the principal and professors of the SSM College of Pharmacy and study Center at BLDEA’s in Vijayapura for their steadfast encouragement and moral support during my research work.
CONFLICT OF INTEREST:
No
REFERENCES:
Anushree Suga , Ashwini Paschapur , Somashekhar M. Metri , Trupti A. Hunnura , Hanamant B. Sannakki , An Approach Of Computer Aided Drug Design (CADD) Tools For In-silico Evaluation Of Various Derivatives Of Antidiabetic Standard Drugs, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 10, 987-997. https://doi.org/10.5281/zenodo.13955358